Article
How I treat endocrine-dependent metastatic breast cancer.
ESMO open - 1 Apr 2023
Gombos A, Goncalves A, Curigliano G, Bartsch R, Kyte J A, Ignatiadis M, Awada A
Abstract excerpt
Estrogen receptor-positive (ER+)/HER2-negative (HER2-), the so-called luminal-type breast cancer, is the most frequent subset, accounting for around 70% of all breast cancer cases. Endocrine therapy (ET) combined with cyclin-dependent kinases (CDK) 4/6 inhibitors is the standard first option in the management of advanced luminal breast cancer independently of disease extension. Classically, patients undergo...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.